Aptose Biosciences (APTO) announced the publication of preclinical data for Aptose’s lead hematology compound tuspetinib in Cancer Research ...
Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and ...
Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical ...
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...
A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...
Medpage Today on MSN3d
Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor"In this high-risk population with relapsed and refractory disease and extensive prior therapy, pirtobrutinib demonstrated ...
A shorter duration of venetoclax treatment for newly diagnosed acute myeloid leukemia (AML) may enhance efficacy and reduce ...
Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...
Initial therapy with sonrotoclax and zanubrutinib showed strong efficacy and acceptable safety in untreated CLL/SLL.
Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic ...
About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease ...
Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback